Compare · AXGN vs TIVC
AXGN vs TIVC
Side-by-side comparison of Axogen Inc. (AXGN) and Tivic Health Systems Inc. (TIVC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and TIVC operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.06B, about 511.7x TIVC ($4.0M).
- TIVC has been more active in the news (11 items in the past 4 weeks vs 6 for AXGN).
- AXGN has more recent analyst coverage (11 ratings vs 0 for TIVC).
- Company
- Axogen Inc.
- Tivic Health Systems Inc.
- Price
- -
- -
- Market cap
- $2.06B
- $4.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 11
- Recent ratings
- 11
- 0
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Tivic Health Systems Inc.
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. The company's primary product, ClearUP, is a medical device intended to relieve sinus and nasal inflammation. It sells its products on direct-to-consumer channel through its own websites and platforms, such as Amazon.com, as well as to major U.S. online retailers, such as BestBuy.com, FSAStore.com, Walgreens.com, Walmart.com. The company was incorporated in 2016 and is headquartered in Newark, California.
Latest AXGN
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
- BofA Securities initiated coverage on AxoGen with a new price target
- Barclays initiated coverage on AxoGen with a new price target
- Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
- Axogen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Latest TIVC
- SEC Form DEF 14A filed by Tivic Health Systems Inc.
- SEC Form 8-K filed by Tivic Health Systems Inc.
- SEC Form 8-K filed by Tivic Health Systems Inc.
- SEC Form 8-K filed by Tivic Health Systems Inc.
- SEC Form S-3 filed by Tivic Health Systems Inc.
- SEC Form 8-K filed by Tivic Health Systems Inc.
- SEC Form PRE 14A filed by Tivic Health Systems Inc.
- Tivic Health Systems Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Interim CEO Zikria Dean
- COO & CFO Wolf Lisa G converted options into 4 shares and covered exercise/tax liability with 2 shares, increasing direct ownership by 8% to 27 units (SEC Form 4) (withholding obligation)